Paper Details

  1. Home
  2. Paper Details

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.

Author: Al-DhabiNaif Abdullah, ArunagirinathanNarasingam, IgnacimuthuSavarimuthu, InduPurushothaman, RameshkumarMarimuthu Ragavan, Valan ArasuMariadhas

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The COVID-19 pandemic has caused high rates of morbidity and mortality globally. There are currently no specific antiviral drugs available for treating COVID-19. This study investigates repurposing FDA-approved small molecule antiviral drugs against the major viral proteins of SARS-CoV-2.
Paper Details　
Original Abstract of the Article :
Outbreak of COVID-19 has been recognized as a global health concern since it causes high rates of morbidity and mortality. No specific antiviral drugs are available for the treatment of COVID-19 till date. Drug repurposing strategy helps to find out the drugs for COVID-19 treatment from existing FDA...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587076/

データ提供：米国国立医学図書館（NLM）

Drug Repurposing for COVID-19 Treatment

The COVID-19 pandemic has highlighted the urgent need for effective antiviral treatments. This study investigated the potential of drug repurposing, using existing FDA-approved antiviral drugs, to combat the SARS-CoV-2 virus. The researchers focused on repurposing drugs against the main protease and RNA-dependent RNA polymerase, two key proteins involved in viral replication.

Potential Antiviral Agents for COVID-19

The study identified several FDA-approved antiviral drugs that showed promising activity against the main protease and RNA-dependent RNA polymerase of SARS-CoV-2. These drugs included raltegravir, indinavir, tipranavir, dolutegravir, and etravirine. Further research is needed to validate these findings and explore their potential as therapeutic agents for COVID-19.

Hope for New Treatments

The drug repurposing approach offers a promising avenue for rapidly identifying potential treatments for COVID-19. By leveraging existing drugs with known safety profiles, researchers can expedite the development of effective therapies and potentially improve patient outcomes.

Dr.Camel's Conclusion

Finding a treatment for COVID-19 is like searching for a hidden oasis in the vast and unpredictable desert of viral infections. Drug repurposing provides a valuable shortcut, potentially leading to new and effective treatments for this global health challenge.

Date :
  1. Date Completed 2020-12-16
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

33168456

DOI: Digital Object Identifier

PMC7587076

Related Literature

Article Analysis
・Effects of etravirine・Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.